spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  DOXIL 

 HSMN NewsFeed - 23 Apr 2021
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jul 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 8 May 2018
TFF Pharmaceuticals Announces Appointment of Glenn Mattes as New Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 3 May 2018
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Oct 2017
SutroVax Appoints Veteran Vaccine Experts to Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Jan 2017
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Dec 2016
Panther Biotechnology Receives Positive Feedback from the FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2012
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 27 Jun 2011
Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2011
Savient Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
TetraLogic Closes $23 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Jul 2010
Spectrum Pharmaceuticals Appoints George Tidmarsh, M.D., Ph.D, as Senior Vice President, Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2010
BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2010
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2009
Endocyte Officials Announce Close of $26 Million Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Sep 2009
FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2009
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jan 2009
Hana Biosciences Appoints Thomas J. Tarlow as Vice President, Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2008
Medivation Announces Senior Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2007
BIND Biosciences, Inc. Closes $16M Series B Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Multiple Myeloma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Study Shows VELCADE(R) Plus DOXIL(R) Improves Survival in Previously Treated Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Oct 2006
Array BioPharma Appoints April H. Teitelbaum, MD, MS, FACP Vice President of Clinical Development - Oncology
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 19

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 19 additional stories matching:
DOXIL
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.